Business Context and Reporting Period
Company: Atyr Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: December 4, 2025
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard (Item 3.01).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing compliance.
Material Changes
- Stock Price Deficiency: The Company received a deficiency notice from Nasdaq stating that for the last 30 consecutive business days prior to December 4, 2025, the closing bid price of its common stock was below $1.00 per share.
- Listing Status: The notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days (until June 2, 2026) to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for 10 consecutive business days.
- Secondary Compliance Option: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period, contingent on meeting market value of publicly held shares and other initial listing standards. This may require a reverse stock split.
- Delisting Risk: Failure to regain compliance by the Compliance Date (or the end of a second period) may result in delisting. The Company may appeal such a determination, though success is not assured.
- Management Action: The Company intends to actively monitor the closing bid price and evaluate options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of ATYR stock relative to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to assess immediate compliance progress.
- Review future filings for announcements regarding a potential reverse stock split or other capital structure changes.
- Check for any subsequent Nasdaq communications regarding the Company's eligibility for a second compliance period.